Needham analyst David Saxon maintains RxSight (NASDAQ:RXST) with a Buy and raises the price target from $19 to $22.
Intelligent Bio Solutions Obtains ISO Recertification For Its Intelligent Fingerprinting Drug Screening Business
Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its Intelligent Fingerprinting Drug
